Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard West

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
American Journal of Clinical Oncology|January 6, 2022
Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC)Jason Liu, Emily Bratton, Xinyan Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibitionDavid R Gandara, Howard West, Kari Chansky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2005
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group StudyFred R Hirsch, Marileila Varella-Garcia, Jason McCoy, et al.
Cancers|August 26, 2022
Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLCJennifer Novak, Ravi Salgia, Howard West, et al.
Journal of Personalized Medicine|September 28, 2023
Pancreatic Adenocarcinoma: Real World Evidence of Care Delivery in AccessHope DataAfsaneh Barzi, Angela J Kim, Crystal K Liang, et al.
Cancer Chemotherapy and Pharmacology|March 30, 2017
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancerHeather A Wakelee, Scott Gettinger, Jeffrey Engelman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinomaMark G Kris, Giuseppe Giaccone, Angela Davies, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 30, 2014
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancerD Ross Camidge, Eamon M Berge, Robert C Doebele, et al.
ESMO Open|July 19, 2018
Patient-reported outcomes in a phase II, North American study of alectinib in patients with <i>ALK</i>-positive, crizotinib-resistant, non-small cell lung cancerSai-Hong Ignatius Ou, Mark A Socinski, Shirish Gadgeel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 4, 2006
Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancerJohn Nemunaitis, Thomas Meyers, Neil Senzer, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
American Journal of Clinical Oncology|January 6, 2022
Patterns of Care in Maintenance Therapy in US Patients Undergoing Definitive Chemoradiation for Stage 3 Non-Small Cell Lung Cancer (NSCLC)Jason Liu, Emily Bratton, Xinyan Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibitionDavid R Gandara, Howard West, Kari Chansky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2005
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group StudyFred R Hirsch, Marileila Varella-Garcia, Jason McCoy, et al.
Cancers|August 26, 2022
Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLCJennifer Novak, Ravi Salgia, Howard West, et al.
Journal of Personalized Medicine|September 28, 2023
Pancreatic Adenocarcinoma: Real World Evidence of Care Delivery in AccessHope DataAfsaneh Barzi, Angela J Kim, Crystal K Liang, et al.
Cancer Chemotherapy and Pharmacology|March 30, 2017
A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancerHeather A Wakelee, Scott Gettinger, Jeffrey Engelman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinomaMark G Kris, Giuseppe Giaccone, Angela Davies, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 30, 2014
A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancerD Ross Camidge, Eamon M Berge, Robert C Doebele, et al.
ESMO Open|July 19, 2018
Patient-reported outcomes in a phase II, North American study of alectinib in patients with <i>ALK</i>-positive, crizotinib-resistant, non-small cell lung cancerSai-Hong Ignatius Ou, Mark A Socinski, Shirish Gadgeel, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 4, 2006
Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancerJohn Nemunaitis, Thomas Meyers, Neil Senzer, et al.
Pageof 5